Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction

Figueiredo, Fábio P.; Brandão, Cynthia; Perez, Renata de Mello; Barbosa, Walnei Fernandes; Kondo, Mário

doi:10.1590/s0004-28032003000300004

Cited by 5 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not find any difference among various age groups; age has been shown to be inversely related to BMD in several, but not in all, studies [15]; narrow age range or other confounding variables affecting BMD, for example nutrition and physical activity (which we did not include), may be responsible for nonsignificant differences, or age may not be an important variable for BMD loss in hepatic osteodystrophy. We found more prevalence of osteodystrophy in males than in females, but our study group had only eight female patients so this may not be significant.…”

Section: Discussioncontrasting

confidence: 67%

“…Other studies addressing differences in the incidence of osteodystrophy between alcohol or viral cirrhosis also did not find any difference [14,15]. Serum PTH and vitamin D are important for bone mineral serum levels.…”

Section: Discussionmentioning

confidence: 92%

“…In this era of long-term survival with end-stage liver disease and liver transplantation it is extremely important, because one study showed 17% fracture rate at the end of one year [3]. Various studies found incidence of hepatic osteodystrophy 38-87% among noncholestatic cirrhosis [13][14][15].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatic Osteodystrophy Is Common in Patients with Noncholestatic Liver Disease

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 67%

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Hepatic Osteodystrophy Is Common in Patients with Noncholestatic Liver Disease

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Fracture rates up to 50% are noticed in liver transplant recipients [3]. Osteoporosis is not only the result of cholestatic disease [4,5]. Hepatitis B and C also as well as alcoholic cirrhosis are associated with osteopenia frequently [6,7].…”

Section: Introductionmentioning

confidence: 99%

Treatment of osteoporosis after liver transplantation with ibandronate

Kaemmerer¹,

Lehmann²,

Wolf³

et al. 2010

Transplant International

View full text Add to dashboard Cite

Summary Osteoporosis is a major side‐effect after liver transplantation (LTX). Therefore, the objective of the study was to evaluate the efficacy of ibandronate to reduce fractures after LTX. Seventy‐four patients after LTX were included in the study and measurements of bone mineral density (BMD) of lumbar spine and proximal femur using dual energy X‐ray absorptiometry (DEXA) were performed prior to and 3, 6, 12 and 24 months after surgery. The study group (IBA) consisted of 34 patients who received calcium (1 g/day), vitamin D3 (800–1000 IE/day) and ibandronate 2 mg every 3 months intravenously for 1 year. The control group consisted of 40 patients (CON) who received calcium and vitamin D3 at the same dosages. Prevalence of new fractures was predefined as primary endpoint. Changes of BMD and biochemical markers of bone metabolism were also investigated. In all patients, we found a reduction of BMD in the first few months after LTX. In the lumbar spine and the proximal femur the maximum reduction occurred 3 and 6 months post‐LTX. One and 2 years after transplantation, the group receiving ibandronate demonstrated a better recovery from loss of BMD and a significantly lower prevalence of fractures (IBA 2 vs. CON 10 P < 0.04, χ2). Ibandronate with calcium and vitamin D3 reduces the BMD‐loss after LTX and decreases the rate of bone fractures significantly.

show abstract

“…This finding disagrees with Tsuneoka et al [29] and Ormarsdottir et al [48] who found that the advanced age of patients was an independent risk factor of osteoporosis in patients with chronic liver disease including chronic hepatitis and cirrhosis. Also Figueiredo et al [49] who found that there was a significantly…”

Section: Discussionmentioning

confidence: 93%

Osteoporosis in Chronic Hepatitis C

Abdelkader

Hegazy

Elbadrawy

et al. 2014

Afro-Egyptian Journal of Infectious and Endemic Diseases

View full text Add to dashboard Cite

Background and study aim: Hepatitis C virus infection is a multisystemic disease with many extrahepatic manifestations. Affection of bone matrix density is a common complication of chronic hepatitis and cirrhosis. The pathogenesis of osteoporosis in chronic liver disease is still unknown and is expected to be multifactorial. The aim of this work is to assess the frequency of osteoporosis/osteopenia in patients with chronic hepatitis C virus infection with or without cirrhosis. Patients and Methods: This study was carried out on 30 patients with chronic HCV infection without cirrhosis (Group II), 30 patients with chronic HCV infection with compensated cirrhosis (Group III) and 20 age and gender matched healthy controls (Group I). All subjects of the study performed liver function tests, viral markers, liver biopsy, hormonal assay and Bone Mineral density measurement (BMD) by Dual energy Xray absorptiometry (DEXA). Results: In patients with chronic hepatitis C (group II) the frequency of osteopenia was 11 (36.7%), osteoporosis 2 (6.7 %), total patients with low BMD was 13 (43.3%). In cirrhotic patients (group III), the frequency of osteopenia was 13 (43.3%), osteoporosis was 3 (10.0%), and total patients with low BMD was 16(53.3%) vs 1(5.0%) in the control group (group I). there was also no significant difference between patients with low BMD and patients with normal BMD as regards age, gender, common risk factors, liver function tests or hormonal levels. Conclusion: Reduced BMD is common chronic HCV-infected patients with and without cirrhosis. HCV infection is a risk factor of osteoporosis.

show abstract

Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction

Cited by 5 publications

References 31 publications

Hepatic Osteodystrophy Is Common in Patients with Noncholestatic Liver Disease

Hepatic Osteodystrophy Is Common in Patients with Noncholestatic Liver Disease

Treatment of osteoporosis after liver transplantation with ibandronate

Osteoporosis in Chronic Hepatitis C

Contact Info

Product

Resources

About